Moschos 2012.

Methods	Study design: Parallel group RCT
Participants	Country: Greece Setting: Eye hospital Intervention: NSAIDs plus steroids Number of people (eyes) randomised: 38 (38) Number (%) of people followed up: NR Average age in years: 77 Age range in years: NR Percentage women: 68% Ethnic group: NR Percentage with diabetes: 0 (excluded) Percentage with uveitis: 0 (excluded) Comparator: Steroids alone Number of people (eyes) randomised: 41 (41) Number (%) of people followed up: NR Average age in years: 77 Age range in years: NR Percentage women: 63% Ethnic group: NR Percentage with diabetes: 0 (excluded) Percentage with uveitis: 0 (excluded) Inclusion criteria: Patients requiring phacoemulsification cataract surgery. Exclusion criteria: Presence of corneal abnormalities; history of intraocular surgery; preoperative ECC < 1500 cells/mm2; history of uveitis, diabetes, and age‐related macular degeneration; regular, systemic use of steroid or NSAIDs during the previous 3 months; and intraoperative complications, such as posterior capsule rupture, vitreous loss, lost nucleus, zonule dehiscence, and wound leak. Pretreatment: No major imbalances noted. Eyes: One eye, unclear how selected.
Interventions	Intervention: NSAIDs plus steroids diclofenac sodium 0.1% (Denaclof, Novartis Hellas, Athens, Greece) Times per day: 3 times Duration preoperative: days: 3 Duration postoperative: days: 28 dexamethasone sodium phosphate 0.1% (combined with chloramphenicol 0.5%) (Dispersadron (Novartis Hellas, Athens, Greece) Times per day: 4 times Duration preoperative: days: 0 Duration postoperative: days: 28 Comparator: Steroids alone dexamethasone sodium phosphate 0.1% (combined with chloramphenicol 0.5%) (Dispersadron, Novartis Hellas, Athens, Greece) Times per day: 4 times Duration preoperative: days: 0 Duration postoperative: days: 28 Type of surgery: Phacoemulsification
Outcomes	Follow‐up: 1 month CRT at follow‐up (final value) BCVA logMAR (final value)
Contact details	Authors name: Irini P. Chatziralli Institution: Department of Ophthalmology University of Athens Email: eirchat@yahoo.gr Address: Department of Ophthalmology, University of Athens, 28 Papanastasiou street 17342 Athens, Greece
Notes	Funding sources: NR Declaration of interest: "No competing financial interests exist." Date study conducted: NR Trial registration number: NR Contacting study investigators: Trial authors not contacted.
Risk of bias
Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Low risk	Quote: "Patients were randomised (through random number generation) to 1 of the 2 postoperative treatment arms."
Allocation concealment (selection bias)	Unclear risk	Judgement comment: Not reported how allocation administered. Trial described as “randomised” but with no further details.
Blinding of participants and personnel (performance bias) All outcomes	High risk	Judgement comment: No information on masking. We assume that in absence of reporting on this patients and personnel were not masked.
Blinding of outcome assessment (detection bias) All outcomes	High risk	Judgement comment: No information on masking. We assume that in absence of reporting on this patients and personnel were not masked.
Incomplete outcome data (attrition bias) All outcomes	Unclear risk	Judgement comment: Follow‐up not reported.
Selective reporting (reporting bias)	Unclear risk	Judgement comment: No access to protocol or trial registry entry.